Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.

This is a Phase 1b, single-cente, randomized, double-blind, placebo-controlled proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and mosquitocidal activity of single oral doses of lotilaner in healthy, adult participants living in Mali.

NCT Number	NCT07758985
Lead Sponsor	Medicines for Malaria Venture Collaborators: Radboud University Medical Center, London School of Hygiene and Tropical Medicine, Malaria Research and Training Center, Bamako, Mali
Conditions	Malaria
Enrollment	75 participants
Start Date	2026-08
Primary Completion	2027-08 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-08-11